$ALTH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALLOS THERAPEUTICS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALLOS THERAPEUTICS INC. Get notifications about new insider transactions in ALLOS THERAPEUTICS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | STOUT DAVID M | Director | Sell | U | 1.82 | 35,000 | 63,700 | 0 | 35 K to 0 (-100.00 %) |
| Sep 06 2012 | ALTH | ALLOS THERAPEUTICS ... | SPECTRUM PHARMACEUTICALS INC | 10% Owner | Buy | P | 1.82 | 130,854,840 | 238,155,809 | 1,000 | -130,853,840 to 1,000 (-100.00 %) |
| Sep 06 2012 | ALTH | ALLOS THERAPEUTICS ... | Warburg Pincus Private Equity ... | Director | Sell | U | 1.82 | 26,124,430 | 47,546,463 | 0 | 26.1 M to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | TURNER JOSEPH L | Director | Sell | U | 1.82 | 55,000 | 100,100 | 0 | 55 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | LEFF JONATHAN S | Director | Sell | U | 1.82 | 55,000 | 100,100 | 0 | 55 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | LATTS JEFFREY | Director | Sell | U | 1.82 | 55,000 | 100,100 | 0 | 55 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | GONZALO CECILIA | Director | Option Exercise | U | 1.39 | 25,000 | 34,750 | 0 | |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Sell | U | 1.82 | 200 | 364 | 0 | 200 to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Sell | U | 1.82 | 200 | 364 | 0 | 200 to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Sell | U | 1.82 | 200 | 364 | 0 | 200 to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Sell | U | 1.82 | 200 | 364 | 0 | 200 to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Sell | U | 1.82 | 472,871 | 860,625 | 0 | 472.9 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Sell | U | 1.82 | 92,000 | 167,440 | 0 | 92 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | U | 1.82 | 285,113 | 518,906 | 0 | 285.1 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Sell | U | 1.82 | 655,031 | 1,192,156 | 0 | 655 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Sell | U | 1.82 | 346,933 | 631,418 | 0 | 346.9 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | U | 1.82 | 542,028 | 986,491 | 0 | 542 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | U | 1.82 | 207,114 | 376,947 | 0 | 207.1 K to 0 (-100.00 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | U | 1.82 | 148,482 | 270,237 | 0 | 148.5 K to 0 (-100.00 %) |
| Jul 13 2012 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 1.78 | 697 | 1,241 | 285,113 | 285.8 K to 285.1 K (-0.24 %) |
| Sep 05 2012 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | U | 1.82 | 1,233,323 | 2,244,648 | 0 | 1.2 M to 0 (-100.00 %) |
| Apr 30 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Buy | P | 1.22 | 1,104 | 1,342 | 148,482 | 147.4 K to 148.5 K (+0.75 %) |
| Apr 30 2012 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Sell | S | 1.81 | 7,970 | 14,426 | 665,323 | 673.3 K to 665.3 K (-1.18 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | S | 1.50 | 3,025 | 4,522 | 147,378 | 150.4 K to 147.4 K (-2.01 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | S | 1.53 | 3,031 | 4,623 | 150,403 | 153.4 K to 150.4 K (-1.98 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Grant | A | 0.00 | 43,862 | 0 | 153,434 | 109.6 K to 153.4 K (+40.03 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 1.50 | 3,385 | 5,073 | 207,114 | 210.5 K to 207.1 K (-1.61 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 1.52 | 3,388 | 5,165 | 210,499 | 213.9 K to 210.5 K (-1.58 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Grant | A | 0.00 | 99,779 | 0 | 213,887 | 114.1 K to 213.9 K (+87.44 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 1.48 | 21,532 | 31,816 | 1,233,323 | 1.3 M to 1.2 M (-1.72 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 1.52 | 21,163 | 32,235 | 1,254,855 | 1.3 M to 1.3 M (-1.66 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Grant | A | 0.00 | 573,506 | 0 | 1,276,018 | 702.5 K to 1.3 M (+81.64 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Sell | S | 1.50 | 4,473 | 6,690 | 346,933 | 351.4 K to 346.9 K (-1.27 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Sell | S | 1.52 | 4,505 | 6,869 | 351,406 | 355.9 K to 351.4 K (-1.27 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Grant | A | 0.00 | 179,727 | 0 | 355,911 | 176.2 K to 355.9 K (+102.01 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 1.48 | 9,635 | 14,260 | 542,028 | 551.7 K to 542 K (-1.75 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 1.52 | 9,425 | 14,366 | 551,663 | 561.1 K to 551.7 K (-1.68 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Grant | A | 0.00 | 222,266 | 0 | 561,088 | 338.8 K to 561.1 K (+65.60 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Sell | S | 1.52 | 10,155 | 15,478 | 673,293 | 683.4 K to 673.3 K (-1.49 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Grant | A | 0.00 | 241,848 | 0 | 683,448 | 441.6 K to 683.4 K (+54.77 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 1.48 | 3,960 | 5,866 | 285,810 | 289.8 K to 285.8 K (-1.37 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 1.52 | 3,894 | 5,935 | 289,770 | 293.7 K to 289.8 K (-1.33 %) |
| Mar 01 2012 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Grant | A | 0.00 | 135,545 | 0 | 293,664 | 158.1 K to 293.7 K (+85.72 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 1.55 | 4,350 | 6,743 | 702,512 | 706.9 K to 702.5 K (-0.62 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 1.56 | 9,100 | 14,196 | 706,862 | 716 K to 706.9 K (-1.27 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | S | 1.55 | 1,469 | 2,277 | 109,572 | 111 K to 109.6 K (-1.32 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | S | 1.58 | 4,484 | 7,085 | 111,041 | 115.5 K to 111 K (-3.88 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Sell | S | 1.54 | 575 | 888 | 176,184 | 176.8 K to 176.2 K (-0.33 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Sell | S | 1.58 | 2,500 | 3,958 | 176,759 | 179.3 K to 176.8 K (-1.39 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 1.55 | 595 | 922 | 114,108 | 114.7 K to 114.1 K (-0.52 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 1.57 | 1,460 | 2,291 | 114,703 | 116.2 K to 114.7 K (-1.26 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 1.58 | 1,645 | 2,599 | 158,119 | 159.8 K to 158.1 K (-1.03 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 1.54 | 1,380 | 2,125 | 338,822 | 340.2 K to 338.8 K (-0.41 %) |
| Feb 27 2012 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 1.58 | 3,950 | 6,254 | 340,202 | 344.2 K to 340.2 K (-1.15 %) |
| Jan 03 2012 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Buy | P | 1.21 | 1,173 | 1,416 | 115,525 | 114.4 K to 115.5 K (+1.03 %) |
| Dec 15 2011 | ALTH | ALLOS THERAPEUTICS ... | DeSilva Nishan M | Director | Grant | A | 0.00 | 35,000 | 0 | 35,000 | 0 to 35 K |
| Dec 15 2011 | ALTH | ALLOS THERAPEUTICS ... | STOUT DAVID M | Director | Grant | A | 0.00 | 35,000 | 0 | 35,000 | 0 to 35 K |
| Dec 15 2011 | ALTH | ALLOS THERAPEUTICS ... | LATTS JEFFREY | Director | Grant | A | 0.00 | 55,000 | 0 | 55,000 | 0 to 55 K |
| Dec 15 2011 | ALTH | ALLOS THERAPEUTICS ... | LEFF JONATHAN S | Director | Grant | A | 0.00 | 55,000 | 0 | 55,000 | 0 to 55 K |
| Dec 15 2011 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Grant | A | 0.00 | 90,000 | 0 | 339,999 | 250 K to 340 K (+36.00 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 1.43 | 125 | 179 | 116,163 | 116.3 K to 116.2 K (-0.11 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 1.45 | 5,438 | 7,861 | 116,288 | 121.7 K to 116.3 K (-4.47 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 1.44 | 14,494 | 20,900 | 344,152 | 358.6 K to 344.2 K (-4.04 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Sell | S | 1.44 | 17,829 | 25,724 | 441,600 | 459.4 K to 441.6 K (-3.88 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 1.43 | 140 | 201 | 159,764 | 159.9 K to 159.8 K (-0.09 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 1.44 | 8,033 | 11,576 | 159,904 | 167.9 K to 159.9 K (-4.78 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 1.43 | 450 | 644 | 715,962 | 716.4 K to 716 K (-0.06 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 1.46 | 31,817 | 46,532 | 716,412 | 748.2 K to 716.4 K (-4.25 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Sell | S | 1.43 | 300 | 430 | 179,259 | 179.6 K to 179.3 K (-0.17 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | SVP, Corporate Deve ... | Sell | S | 1.44 | 12,465 | 18,008 | 179,559 | 192 K to 179.6 K (-6.49 %) |
| Nov 17 2011 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | S | 1.44 | 26,100 | 37,707 | 114,352 | 140.5 K to 114.4 K (-18.58 %) |
| Jul 13 2011 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 2.06 | 730 | 1,505 | 167,937 | 168.7 K to 167.9 K (-0.43 %) |
| Jul 01 2011 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Buy | P | 1.82 | 772 | 1,404 | 140,452 | 139.7 K to 140.5 K (+0.55 %) |
| Jun 23 2011 | ALTH | ALLOS THERAPEUTICS ... | STOUT DAVID M | Director | Option Exercise | A | 2.06 | 20,000 | 41,200 | 20,000 | |
| Jun 23 2011 | ALTH | ALLOS THERAPEUTICS ... | LYNCH TIMOTHY P | Director | Option Exercise | A | 2.06 | 20,000 | 41,200 | 20,000 | |
| Jun 23 2011 | ALTH | ALLOS THERAPEUTICS ... | LEFF JONATHAN S | Director | Option Exercise | A | 2.06 | 20,000 | 41,200 | 20,000 | |
| Jun 23 2011 | ALTH | ALLOS THERAPEUTICS ... | LATTS JEFFREY | Director | Option Exercise | A | 2.06 | 20,000 | 41,200 | 20,000 | |
| Jun 23 2011 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Option Exercise | A | 2.06 | 30,000 | 61,800 | 30,000 | |
| Jun 23 2011 | ALTH | ALLOS THERAPEUTICS ... | DeSilva Nishan M | Director | Option Exercise | A | 2.06 | 20,000 | 41,200 | 20,000 | |
| Apr 29 2011 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Sell | S | 2.84 | 9,800 | 27,825 | 459,429 | 469.2 K to 459.4 K (-2.09 %) |
| Mar 02 2011 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Grant | A | 0.00 | 65,000 | 0 | 168,667 | 103.7 K to 168.7 K (+62.70 %) |
| Mar 18 2011 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Option Exercise | M | 3.14 | 2,500 | 7,850 | 347,500 | |
| Mar 18 2011 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Buy | M | 3.14 | 2,500 | 7,850 | 748,229 | 745.7 K to 748.2 K (+0.34 %) |
| Mar 02 2011 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Grant | A | 0.00 | 185,851 | 0 | 469,229 | 283.4 K to 469.2 K (+65.58 %) |
| Mar 02 2011 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Grant | A | 0.00 | 170,803 | 0 | 358,646 | 187.8 K to 358.6 K (+90.93 %) |
| Mar 02 2011 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | VP, Corporate Devel ... | Grant | A | 0.00 | 67,298 | 0 | 192,024 | 124.7 K to 192 K (+53.96 %) |
| Mar 02 2011 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Grant | A | 0.00 | 53,957 | 0 | 121,726 | 67.8 K to 121.7 K (+79.62 %) |
| Mar 02 2011 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Grant | A | 0.00 | 345,942 | 0 | 745,729 | 399.8 K to 745.7 K (+86.53 %) |
| Mar 02 2011 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Grant | A | 0.00 | 43,765 | 0 | 139,680 | 95.9 K to 139.7 K (+45.63 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 3.13 | 1,410 | 4,406 | 187,843 | 189.3 K to 187.8 K (-0.75 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 3.24 | 3,800 | 12,318 | 189,253 | 193.1 K to 189.3 K (-1.97 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 3.12 | 557 | 1,740 | 67,769 | 68.3 K to 67.8 K (-0.82 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 3.25 | 1,365 | 4,439 | 68,326 | 69.7 K to 68.3 K (-1.96 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 3.12 | 4,255 | 13,293 | 399,787 | 404 K to 399.8 K (-1.05 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | S | 3.25 | 9,193 | 29,878 | 404,042 | 413.2 K to 404 K (-2.22 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | S | 3.20 | 1,469 | 4,701 | 95,915 | 97.4 K to 95.9 K (-1.51 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Sell | S | 3.23 | 4,484 | 14,486 | 97,384 | 101.9 K to 97.4 K (-4.40 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Sell | S | 3.25 | 1,570 | 5,105 | 103,667 | 105.2 K to 103.7 K (-1.49 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | VP, Corporate Devel ... | Sell | S | 3.12 | 507 | 1,583 | 124,726 | 125.2 K to 124.7 K (-0.40 %) |
| Feb 25 2011 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | VP, Corporate Devel ... | Sell | S | 3.25 | 2,250 | 7,313 | 125,233 | 127.5 K to 125.2 K (-1.76 %) |
| Jan 04 2011 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Buy | P | 3.92 | 333 | 1,305 | 101,868 | 101.5 K to 101.9 K (+0.33 %) |
| Oct 22 2010 | ALTH | ALLOS THERAPEUTICS ... | Schick Michael E | VP, Sales and Marke ... | Grant | A | 0.00 | 78,300 | 0 | 105,237 | 26.9 K to 105.2 K (+290.68 %) |
| Oct 22 2010 | ALTH | ALLOS THERAPEUTICS ... | Morris Charles Q | Chief Medical Offic ... | Grant | A | 0.00 | 173,378 | 0 | 283,378 | 110 K to 283.4 K (+157.62 %) |
| Oct 22 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Grant | A | 0.00 | 134,228 | 0 | 193,053 | 58.8 K to 193.1 K (+228.18 %) |
| Oct 22 2010 | ALTH | ALLOS THERAPEUTICS ... | Goldsmith Bruce A | VP, Corporate Devel ... | Grant | A | 0.00 | 100,671 | 0 | 127,483 | 26.8 K to 127.5 K (+375.47 %) |
| Oct 22 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Grant | A | 0.00 | 50,336 | 0 | 69,691 | 19.4 K to 69.7 K (+260.07 %) |
| Oct 22 2010 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Grant | A | 0.00 | 78,300 | 0 | 101,535 | 23.2 K to 101.5 K (+336.99 %) |
| Oct 22 2010 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Grant | A | 0.00 | 265,734 | 0 | 413,235 | 147.5 K to 413.2 K (+180.16 %) |
| Jul 02 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Buy | P | 5.21 | 913 | 4,757 | 58,825 | 57.9 K to 58.8 K (+1.58 %) |
| Jul 02 2010 | ALTH | ALLOS THERAPEUTICS ... | BENNETT BRUCE K JR | VP, Pharmaceutical ... | Buy | P | 5.21 | 233 | 1,214 | 23,235 | 23 K to 23.2 K (+1.01 %) |
| Jun 24 2010 | ALTH | ALLOS THERAPEUTICS ... | HOFFMAN STEPHEN J | Director | Option Exercise | A | 6.34 | 30,000 | 190,200 | 30,000 | |
| Jun 24 2010 | ALTH | ALLOS THERAPEUTICS ... | STOUT DAVID M | Director | Option Exercise | A | 6.34 | 20,000 | 126,800 | 20,000 | |
| Jun 24 2010 | ALTH | ALLOS THERAPEUTICS ... | LYNCH TIMOTHY P | Director | Option Exercise | A | 6.34 | 20,000 | 126,800 | 20,000 | |
| Jun 24 2010 | ALTH | ALLOS THERAPEUTICS ... | LEFF JONATHAN S | Director | Option Exercise | A | 6.34 | 20,000 | 126,800 | 20,000 | |
| Jun 24 2010 | ALTH | ALLOS THERAPEUTICS ... | LATTS JEFFREY | Director | Option Exercise | A | 6.34 | 20,000 | 126,800 | 20,000 | |
| May 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Option Exercise | M | 2.93 | 2,251 | 6,595 | 0 | |
| May 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Option Exercise | M | 2.70 | 834 | 2,252 | 0 | |
| May 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Buy | M | 2.93 | 2,251 | 6,595 | 19,355 | 17.1 K to 19.4 K (+13.16 %) |
| May 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 7.03 | 3,085 | 21,684 | 17,104 | 20.2 K to 17.1 K (-15.28 %) |
| May 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Buy | M | 2.70 | 834 | 2,252 | 20,189 | 19.4 K to 20.2 K (+4.31 %) |
| Apr 14 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Option Exercise | M | 2.70 | 75,000 | 202,500 | 0 | |
| Apr 14 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 8.58 | 75,000 | 643,530 | 57,912 | 132.9 K to 57.9 K (-56.43 %) |
| Apr 14 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Buy | M | 2.70 | 75,000 | 202,500 | 132,912 | 57.9 K to 132.9 K (+129.51 %) |
| Mar 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Option Exercise | M | 4.78 | 20,000 | 95,600 | 0 | |
| Mar 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 7.78 | 20,000 | 155,612 | 19,355 | 39.4 K to 19.4 K (-50.82 %) |
| Mar 12 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Buy | M | 4.78 | 20,000 | 95,600 | 39,355 | 19.4 K to 39.4 K (+103.33 %) |
| Mar 11 2010 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | D | 7.45 | 41,350 | 308,157 | 147,501 | 188.9 K to 147.5 K (-21.90 %) |
| Mar 11 2010 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Sell | D | 7.25 | 33,650 | 244,010 | 188,851 | 222.5 K to 188.9 K (-15.12 %) |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Option Exercise | M | 2.93 | 10,000 | 29,300 | 2,251 | |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Option Exercise | M | 2.93 | 582 | 1,705 | 12,251 | |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Option Exercise | M | 2.70 | 8,333 | 22,499 | 834 | |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 7.02 | 10,000 | 70,196 | 19,355 | 29.4 K to 19.4 K (-34.07 %) |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Buy | M | 2.93 | 10,000 | 29,300 | 29,355 | 19.4 K to 29.4 K (+51.67 %) |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Sell | S | 6.98 | 11,640 | 81,301 | 19,355 | 31 K to 19.4 K (-37.55 %) |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Buy | M | 2.93 | 582 | 1,705 | 30,995 | 30.4 K to 31 K (+1.91 %) |
| Mar 08 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Buy | M | 2.70 | 8,333 | 22,499 | 30,413 | 22.1 K to 30.4 K (+37.74 %) |
| Mar 03 2010 | ALTH | ALLOS THERAPEUTICS ... | CARUSO JAMES V | Chief Commercial Of ... | Option Exercise | M | 3.13 | 40,000 | 125,200 | 60,000 | |
| Mar 03 2010 | ALTH | ALLOS THERAPEUTICS ... | CARUSO JAMES V | Chief Commercial Of ... | Sell | S | 8.13 | 37,500 | 304,875 | 103,659 | 141.2 K to 103.7 K (-26.57 %) |
| Mar 03 2010 | ALTH | ALLOS THERAPEUTICS ... | CARUSO JAMES V | Chief Commercial Of ... | Sell | S | 8.13 | 40,000 | 325,204 | 141,159 | 181.2 K to 141.2 K (-22.08 %) |
| Mar 03 2010 | ALTH | ALLOS THERAPEUTICS ... | CARUSO JAMES V | Chief Commercial Of ... | Buy | M | 3.13 | 40,000 | 125,200 | 181,159 | 141.2 K to 181.2 K (+28.34 %) |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Option Exercise | A | 7.56 | 73,083 | 552,507 | 73,083 | |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 7.44 | 2,349 | 17,477 | 57,912 | 60.3 K to 57.9 K (-3.90 %) |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Sell | S | 7.51 | 1,416 | 10,634 | 60,261 | 61.7 K to 60.3 K (-2.30 %) |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | Graboyes Marc H | SVP, General Counse ... | Grant | A | 0.00 | 41,617 | 0 | 61,677 | 20.1 K to 61.7 K (+207.46 %) |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Option Exercise | A | 7.56 | 26,250 | 198,450 | 26,250 | |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | Clark David C | VP, Finance | Grant | A | 0.00 | 14,948 | 0 | 22,080 | 7.1 K to 22.1 K (+209.59 %) |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | CARUSO JAMES V | Chief Commercial Of ... | Option Exercise | A | 7.56 | 102,300 | 773,388 | 102,300 | |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | CARUSO JAMES V | Chief Commercial Of ... | Sell | S | 7.44 | 5,968 | 44,378 | 141,159 | 147.1 K to 141.2 K (-4.06 %) |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | CARUSO JAMES V | Chief Commercial Of ... | Grant | A | 0.00 | 58,254 | 0 | 147,127 | 88.9 K to 147.1 K (+65.55 %) |
| Feb 24 2010 | ALTH | ALLOS THERAPEUTICS ... | BERNS PAUL L | Chief Executive Off ... | Option Exercise | A | 7.56 | 170,000 | 1,285,200 | 170,000 |